Microbial Pathogenicity: A New Approach to Drug Development

被引:7
作者
Chakrabarty, Ananda M. [1 ]
机构
[1] Univ Illinois, Coll Med, Dept Microbiol & Immunol, Chicago, IL 60612 USA
来源
INFECTIOUS DISEASES AND NANOMEDICINE II | 2014年 / 808卷
关键词
Microbial pathogenicity; Infectious diseases; Drug development; Cancer; THERAPY; TUMORS;
D O I
10.1007/978-81-322-1774-9_4
中图分类号
Q81 [生物工程学(生物技术)]; Q93 [微生物学];
学科分类号
071005 [微生物学]; 090105 [作物生产系统与生态工程];
摘要
Pathogenic microorganisms, particularly pathogenic bacteria that cause debilitating diseases, are considered a threat for human health and well-being. Infectious diseases are rampant, particularly in developing countries. However, there are many other deadly diseases, such as cancer, diabetes, cardiac malfunction, etc., that account for significant loss of life and trauma in our society. In this article, I try to describe the role certain bacterial pathogens with long term residence in the human body can play in providing us with our next generation anticancer and other drugs, demonstrating that a certain amount of good can come out of such bacterial pathogens as well.
引用
收藏
页码:41 / 49
页数:9
相关论文
共 11 条
[1]
Overcoming drug resistance in multi-drug resistant cancers and microorganisms A conceptual framework [J].
Avner, Benjamin S. ;
Fialho, Arsenio M. ;
Chakrabarty, Ananda M. .
BIOENGINEERED, 2012, 3 (05) :262-270
[2]
Engineering of bacterial strains and their products for cancer therapy [J].
Bernardes, Nuno ;
Chakrabarty, Ananda M. ;
Fialho, Arsenio M. .
APPLIED MICROBIOLOGY AND BIOTECHNOLOGY, 2013, 97 (12) :5189-5199
[3]
Fialho A., 2010, Emerging cancer therapy : microbial approaches and biotechnological tools
[4]
Fialho AM, 2012, ISRN NEUROLOGY, DOI 10.5402/2012/642345
[5]
Fialho AM, 2010, Emerging cancer therapy: microbial approaches and biotechnological tools, P181, Patent No. [7618939, 7,618,939]
[6]
Patent controversies and court cases Cancer diagnosis, therapy and prevention [J].
Fialho, Arsenio M. ;
Chakrabarty, Ananda M. .
CANCER BIOLOGY & THERAPY, 2012, 13 (13) :1229-1234
[7]
Hong C., 2010, US Patent, Patent No. [7,807,183, 7807183]
[8]
Disrupting the entry barrier and attacking brain tumors -: The role of the Neisseria H.8 epitope and the Laz protein [J].
Hong, Chang Soo ;
Yamada, Tohru ;
Hashimoto, Wataru ;
Fialho, Arsenio M. ;
Das Gupta, Tapas K. ;
Chakrabarty, Ananda M. .
CELL CYCLE, 2006, 5 (15) :1633-1641
[9]
mTOR as a multifunctional therapeutic target in HIV infection [J].
Nicoletti, Ferdinando ;
Fagone, Paolo ;
Meroni, PierLuigi ;
McCubrey, James ;
Bendtzen, Klaus .
DRUG DISCOVERY TODAY, 2011, 16 (15-16) :715-721
[10]
A first-in-class, first-in-human phase I trial of p28, a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in patients with metastatic refractory solid tumors. [J].
Richards, J. M. ;
Warso, M. A. ;
Mehta, D. ;
Christov, K. ;
Schaeffer, C. M. ;
Yamada, T. ;
Beattie, C. W. ;
Bressler, L. R. ;
Das Gupta, T. K. .
JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)